← FDA DRUG APPROVALS

FDA ANDA · ANDA077517

ONDANSETRON HYDROCHLORIDE

Sponsor: CHARTWELL RX

APPLICATION
ANDA077517
TYPE
ANDA
ORIGINAL APPROVAL
2007-06-25
LATEST ACTION
2018-03-08
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

ONDANSETRON HYDROCHLORIDEDiscontinued
ONDANSETRON HYDROCHLORIDE EQ 8MG BASE · TABLET · ORAL
ONDANSETRON HYDROCHLORIDEDiscontinued
ONDANSETRON HYDROCHLORIDE EQ 24MG BASE · TABLET · ORAL
ONDANSETRON HYDROCHLORIDEDiscontinued
ONDANSETRON HYDROCHLORIDE EQ 4MG BASE · TABLET · ORAL

Approval history

2018-03-08Labeling · Supplement 10 · standardAP
2015-01-15Labeling · Supplement 9 · standardAP
2015-01-15Labeling · Supplement 7 · standardAP
2013-03-12Labeling · Supplement 3AP
2012-04-30Labeling · Supplement 5AP
2007-06-25UNKNOWN · Supplement 2 · standardAP
2007-06-25OriginalAP
2007-06-25UNKNOWN · Supplement 1 · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →